Bayer said on Wednesday it struck a global licence agreement for an experimental oral cancer drug for targeted therapies with ...

With the popular social media app once again at risk of going dark, there are best practices pharma brands can use on other ...

The last time a new class of antibiotics reached the market was nearly three decades ago - but that could soon change, thanks to a discovery by researchers at McMaster University. A small molecule ...

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Biohaven Pharmaceutical Holding Co (NYSE:BHVN) Ltd on Tuesday,... Wedbush analyst Laura Chico maintained a Buy rating on Biohaven ...

While the access to combination treatments problem is nothing new, its sheer magnitude means it has, to date, gone unsolved. But now, an initiative spearheaded by Takeda is starting to shift the dial.

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Biohaven Pharmaceutical Holding Co (NYSE:BHVN) Ltd on Tuesday,... H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on ...

Piper Sandler analyst Allison Bratzel maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report) today and set a price target of $76.00. See what stocks are receiving Strong Buy ratings ...

Principal Financial Group Inc. raised its holdings in Biohaven Ltd. (NYSE:BHVN – Free Report) by 4.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned ...

HC Wainwright reissued their buy rating on shares of Biohaven (NYSE:BHVN – Free Report) in a report issued on Tuesday,Benzinga reports. The firm currently has a $54.00 price target on the stock.

Today, a brief rundown of news involving Acelyrin and Neumora Therapeutics, as well as updates from Biohaven, Lexicon Pharmaceuticals and Pliant Therapeutics you may have missed. Shares of Lexicon ...

Biohaven acquired BHV-7000 as part of a February 2022 buyout of Channel Biosciences. Image credit: Shutterstock / ma_Design. Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint ...